CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TreatPolyQ is a collaborative network focused on understanding and treating polyglutamine diseases, such as Huntington’s disease. It brings together experts to explore disease mechanisms and potential therapies, aiming to improve outcomes for patients with neurodegenerative disorders.
Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ).
The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of model diseases and treatment approaches.
The “TreatPolyQ” network will focus on two main representative…
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Paris
Type: Research institute
Activity type: Research Organisations
SME: No
Denmark, COPENHAGEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
